Schedule

November 4 - 6, 2011
Bethesda North Marriott Hotel & Conference Center
North Bethesda, MD

 

Program Schedule

To view slides from a presenter click the icon next to the presentation title.

Friday, November 4 
7:50 am - 8:00 am President's Welcome
Thomas F. Gajewski, MD, PhD - University of Chicago
8:00 am - 8:45 am Richard V. Smalley, MD Memorial Lectureship
Vaccines That Target Dendritic Cells
Ralph M. Steinman, MD - The Rockefeller University
Speaker :  TBD
8:45 am - 11:30 am

 
Plenary Session:  Biology & Application of Dendritic Cells
Co-Chairs:    Nina Bhardwaj, MD, PhD - NYU Medical Center
                     Viggo Van Tendeloo, PhD - Antwerp University Hospital

Invited
Speakers:     Nina Bhardwaj, MD, PhD - NYU Medical Center
                     Robert Seder, MD - NIAID, NIH
                     Viggo Van Tendeloo, PhD - Antwerp University Hospital
8:45 am - 9:15 am PresentationOptimizing T Cell Immunity with Prime-Boost Immunization Using Viral and
Protein/Adjuvant Based Vaccines

Robert A. Seder, MD - NIAID, NIH
9:15 am - 9:30 am Human Langerhans Dendritic Cells Stimulate Robust Cytolytic T-Cells Against Tumor
Antigens, Including WT1, by an IL15-Dependent Mechanism

Emanuela Romano, MD - University Hospital of Lausanne
9:30 am - 10:00 am Dendritic Cell Vaccines for Leukemia in an Adjuvant Post-remission Setting
Viggo Van Tendeloo, PhD - Antwerp University Hospital
10:00 am - 10:15 am The Host STING Pathway is Critical for Innate Immune Sensing at a Growing Tumor and Bridging to an Adaptive Immune Response via IFN-beta
Seng-Ryong Woo, PhD - University of Chicago
10:15 am - 10:45 am Break
10:45 am - 11:00 am PresentationAdenovirus-Engineered Human Dendritic Cell Vaccine Induces Natural Killer Cell
Chemotaxis via CXCL8/IL-8 and CXCL10/IP-10 Chemokines

Lazar Vujanovic, PhD - University of Pittsburgh
11:00 am - 11:30 am Modulation of Dendritic Cell Function by the Tumor Microenvironment
Nina Bhardwaj, MD, PhD - NYU School of Medicine
11:30 am - 12:00 pm Plenary Session: Late Breaking Oral Abstracts
Moderator:    Francesco Marincola, MD - National Institutes of Health
11:30 am - 11:45 am PresentationPhase I Study of Intravenous Recombinant Human Interleukin-15 (RH IL-15) in Adults with Metastatic Malignant Melanoma and Renal Cell Carcinoma
Kevin C. Conlon, MD, MS - National Cancer Institute, NIH
11:45 am - 12:00 pm Reversal of Local Immune Evasion Mechanisms and Regression of Human Merkel Cell Carcinoma by Intralesional Injection of Interferon-Beta
Kelly G. Paulson - University of Washington
12:00 pm - 1:30 pm Lunch Break & Poster Viewing
12:30 pm - 1:30 pm Odd Numbered Poster Presentations by Authors
1:30 pm - 3:00 pm


 
Concurrent Session I:  Immunology of Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)
Co-Chairs:     Malcolm A.S. Moore, D.Phil - Memorial Sloan-Kettering Cancer Center
                      Jeffrey Schlom, PhD - National Cancer Institute, NIH
Invited
Speakers:     Malcolm A.S. Moore, D.Phil - Memorial Sloan-Kettering Cancer Center
                     Claudia M. Palena, PhD - National Cancer Institute, NIH
1:30 pm - 2:00 pm Cancer Testis (CT) Antigens Expressed in Ovarian Tumor-Initiating Cells
Malcolm A.S. Moore, DPhil - Memorial Sloan-Kettering Cancer Center
2:00 pm - 2:30 pm Immunotherapeutic Approaches to EMT and Cancer Stem Cells
Claudia M. Palena, PhD - National Cancer Institute, NIH
2:30 pm - 2:45 pm Immunological Targeting of Epithelial to Mesenchymal Transition as a Strategy to
Prevent Breast Cancer Metastases

Sandra Demaria, MD - New York University School of Medicine
2:45 pm - 3:00 pm Potential for Immunotherapeutic Control of CSC-like Cells Through their Expression of FAS and DR5 Death Receptors
Trina Stewart, PhD - Peter MacCallum Cancer Centre
1:30 pm - 3:00 pm

 
Concurrent Session II: Uncoupling Negative Regulation in the Tumor Microenvironment
Co-Chairs:    Lieping Chen, MD, PhD - Yale University
                     Hassane M. Zarour, MD - University of Pittsburgh

Invited
Speakers:     Lieping Chen, MD, PhD - Yale University
                     Hassane M. Zarour, MD - University of Pittsburgh
1:30 pm - 2:00 pm Immune Checkpoints in the Cancer Microenvironment
Lieping Chen, MD, PhD - Yale Cancer Center, Yale School of Medicine, Immunobiology
2:00 pm - 2:15 pm PresentationIL-12 Triggers an Inflammatory Gene Signature that Reverses Dysfunctional
Antigen-presentation by Myeloid-Derived Cells Residing within Tumors

Sid Kerkar, MD - National Cancer Institute, Center for Cancer Research, NIH
2:15 pm - 2:30 pm PresentationAcute Myeloid Leukemia Promotes Immune Evasion through Induction of Antigen-Specific T Cell Deletion
Justin P. Kline, MD - University of Chicago
2:30 pm - 3:00 pm Targeting Multiple Inhibitory Pathways to Reverse Melanoma-induced T Cell Dysfunction
Hassane M. Zarour, MD - University of Pittsburgh
3:00 pm - 3:15 pm Break
3:15 pm - 5:15 pm


 
Plenary Session:  Genetically Engineered Receptors and Adoptive Cell Therapies
Co-Chairs:     Carl H. June, MD - University of Pennsylvania
                     
Dolores J. Schendel, PhD - Helmholz Zentrum Muenchen -
                                                                 German Research Center for Environmental Health

Invited
Speakers:     Laurence J.N. Cooper, MD, PhD - MD Anderson Cancer Center
                     Carl H. June, MD - University of Pennsylvania
                    
Dolores J. Schendel, PhD - Helmholz Zentrum Muenchen -
                                                                 German Research Center for Environmental Health
3:15 pm - 3:45 pm PresentationGenetically Engineered Receptors in Adoptive Cell Therapies
Laurence J.N. Cooper, MD, PhD - MD Anderson Cancer Center
3:45 pm - 4:15 pm PresentationSelection of Allo-Restricted Peptide-Specific TCRs for Adoptive T Cell Therapy
Dolores J. Schendel, PhD - Helmholtz Zentrum Muenchen - German Research Center for
Environmental Health Institute of Molecular Immunology
4:15 pm - 4:30 pm PresentationDifferential Gene Expression Associated with Immune Down Regulation in TCR
Gene-engineered T Cells Administered to Patients

Daniel Abate-Daga, PhD - National Cancer Institute
4:30 pm - 4:45 pm PresentationActive STAT5 Promotes Long-Lived Cytotoxic CD8 T Cells that Induce Regression of
Autochthonous Mouse Melanoma

Gregory Verdeil, PhD - Centre d’Immunologie de Marseille-Luminy, CIML
4:45 pm - 5:15 pm Engineered T Cell Therapies for Hematologic Malignancies
Carl H. June, MD - University of Pennsylvania
5:15 pm - 5:45 pm Plenary Session: Cancer Immunotherapy Trials Network (CITN) Update
Speaker:       Mary L. (Nora) Disis, MD - Co-Principal Investigator, Cancer Immunotherapy Trials
                                                            Network (CITN);
University of Washington
5:45 pm - 6:15 pm SITC Membership Business Meeting
Immediately Following
the Business Meeting
8:00 pm
Poster & Networking Reception
6:15 pm - 7:00 pm Odd Numbered Poster Presentations by Authors
7:15 pm - 8:00 pm Even Numbered Poster Presentations by Authors
   
Saturday, November 5
8:00 am - 8:45 am Keynote Address: Innate Immune Recognition of Nucleic Acids
Katherine Fitzgerald, PhD - University of Massachusetts Medical School
8:45 am - 11:30 am

 
Plenary Session:  Characterization of Inflammatory Infiltrates in Human Cancers
Co-Chairs:     George Coukos, MD, PhD - University of Pennsylvania Medical Center
                      Wolf-Hervé Fridman, MD, PhD - INSERM
Invited
Speakers:      Vincenzo Bronte, MD - Verona University - Immunology Section
                      George Coukos, MD, PhD - University of Pennsylvania Medical Center
                      Wolf-Hervé Fridman, MD, PhD - INSERM
8:45 am - 9:15 am Chemokine Regulation of T Cell Response in Ovarian Cancer
George Coukos, MD, PhD - University of Pennsylvania Medical Center
9:15 am - 9:30 am PresentationDC Vaccination Concurrently Reduces Treg and Enhances Activated CTL in Tumor Biopsies from Immunoresponsive Patients with Advanced Melanoma
Massimo Guidoboni, MD - Immunology & Somatic Cell Therapy Lab
9:30 am - 10:00 am PresentationContrasted Prognostic Impact of Tumor Infiltration by Various Subsets of Immune Cells
Wolf Hervé Fridman, MD, PhD - INSERM
10:00 am - 10:15 am PresentationTopical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Breast Cancer Skin Metastases
Sylvia Adams, MD - NYU Cancer Institute
10:15 am - 10:45 am Break
10:45 am - 11:00 am PresentationSerial Imaging of Inflammation and Therapeutic Response with Clinically Translational 19F MRI
Amy K. Wesa, PhD - Celsense, Inc
11:00 am - 11:30 am Post-translational Chemokine Modification Prevents Intratumoral Infiltration of Antigen-specific T Cells
Vincenzo Bronte, MD - Verona University - Immunology Section
11:30 am - 12:00 pm Plenary Session: Late Breaking Abstracts
Moderator:   Francisco Marincola, MD - National Institutes of Health
11:30 am - 11:45 am PresentationFrequency of Strong Antibody Responses Following Combination Immunotherapy Correlates with Increased PSA Doubling Time in Men with Androgen-Independent Prostate Cancer
Sachin Puri, PhD - Earle A. Chiles Research Institute
11:45 am - 12:00 pm PresentationIDO1 Activity Correlates with Hepatocyte Growth Factor Levels and Immune System Impairment in Multiple Myeloma
Sergio Rutella, MD, PhD - IRCCS Bambino Gesù Children’s Hospital
12:00 pm - 1:30 pm Lunch Break & Poster Viewing
12:30 pm - 1:30 pm Even Numbered Poster Presentations by Authors
1:30 pm - 3:00 pm
 
Concurrent Session I:  State of the Art Animal Models and Veterinary Applications for Cancer and Immunology
Co-Chairs:     Thomas Blankenstein, PhD - Max-Delbruck Center for Molecular Medicine
                      Jedd D. Wolchok, MD, PhD - Memorial Sloan-Kettering Cancer Center
Invited
Speakers:      Thomas Blankenstein, PhD - Max-Delbruck Center for Molecular Medicine
                       Taha Merghoub, PhD - Memorial Sloan-Kettering Cancer Center
1:30 pm - 2:00 pm The Immune Response to Sporadic Antigenic Cancer
Thomas Blankenstein, PhD - Max-Delbruck Center for Molecular Medicine
2:00 pm - 2:15 pm NOD/scid IL2Rgnull Mice: A Model for Human Dendritic Cell-Based Immunotherapies
Stefani Spranger - Helmholtz Zentrum München
2:15 pm - 2:30 pm PresentationIntracranial Administration of Human Activated NK Cells in a Xenogeneic Model of Orthotopic Glioblastoma
William J. Murphy, PhD - University of California-Davis
2:30 pm - 3:00 pm Overcoming Vaccine Resistance in a Model of Spontaneous Melanoma
Taha Merghoub, PhD - Memorial Sloan-Kettering Cancer Center
1:30 pm - 3:00 pm
 
Concurrent Session II:  High Throughput Technologies for Immune Monitoring
Co-Chairs:     Philipp Beckhove, MD - German Cancer Research Center
                      Sacha Gnjatic, PhD - Ludwig Institute for Cancer Research
Invited
Speakers:     Philipp Beckhove, MD - German Cancer Research Center
                     Sacha Gnjatic, PhD - Ludwig Institute for Cancer Research
1:30 pm - 2:00 pm Tumour Reactive T Cell Responses as Biomarkers: Correlation to Tumour Cell Biology and Treatment Response
Philipp Beckhove, MD - German Cancer Research Center
2:00 pm - 2:15 pm PresentationImmunological Correlates of Long-Term Survival in Melanoma Patients
Graham Pawelec, PhD - University of Tuebingen
2:15 pm - 2:30 pm New Biomarkers for PROSTVAC-VF Discovered Using High-Throughput Glycan Microarrays
Christopher Campbell, MD, PhD - National Cancer Institute
2:30 pm - 3:00 pm Seromics: Measuring Antigen-Specific Serum Antibody Responses During Anticancer Immunotherapies for Correlation with Clinical Events
Sacha Gnjatic, PhD - Ludwig Institute for Cancer Research
3:00 pm - 3:30 pm Break
3:30 pm - 4:50 pm
 
Presidential Abstract Session
Chair:             Thomas F. Gajewski, MD, PhD - University of Chicago
3:30 pm - 3:50 pm PresentationImmunotransplant for Mantle Cell Lymphoma: a Phase I/II Study Demonstrating Amplification of Tumor-Reactive T Cells
Joshua Brody, MD - Stanford University Medical Center
3:50 pm - 4:10 pm PresentationIRF5 Gene Polymorphism in Melanoma
Lorenzo Uccellini, PhD - National Institutes of Health, CC, DTM
4:10 pm - 4:30 pm Improved in Vivo Persistence of CD19-Specific T Cells Expressing a Membrane-Bound Form of IL-15
Lenka Hurton - M.D. Anderson Cancer Center
4:30 pm - 4:50 pm PresentationDysfunctional Tumor-Infiltrating T Cells Express the Anergy-Associated Molecules Lymphocyte-Activation Gene 3 (LAG3) and Class-I-MHC Restricted T Cell Associated Molecules (CRTAM)
Yan Zheng, PhD - University of Chicago
4:50 pm - 5:20 pm PresentationClinical Immunotherapy Guidelines Update
Speaker:         Howard L. Kaufman, MD - Rush University Medical Center   
5:20 pm - 5:35 pm PresentationNational Cancer Institute, NIH Update
Speaker:         William Merritt, PhD - National Cancer Institute
5:35 pm - 5:50 pm FDA Update on Regulatory Issues Related to Cancer Immunotherapy
Speaker:         Raj K. Puri, MD, PhD - Food and Drug Administration, CBER
5:50 pm - 6:15 pm Award Presentations
6:15 pm - 8:00 pm Presidential Reception with Exhibits/Poster Viewing and Presentations  
After 8:00 pm/
Presidential
Reception
Performance by the band The Checkpoints  
Sunday, November 6
8:00 am - 10:15 am

 
Plenary Session:  Prostate Cancer as a Learning Model
Co-Chairs:   Charles G. Drake, MD, PhD - Johns Hopkins University
                    James L. Gulley, MD, PhD - National Cancer Institute
Invited
Speakers:    Charles G. Drake, MD, PhD - Johns Hopkins University
                    James L. Gulley, MD, PhD - National Cancer Institute
                    Douglas G. McNeel, MD, PhD - University of Wisconsin
8:00 am - 8:30 am Immune Checkpoint Blockade in Prostate and Other Cancers
Charles G. Drake, MD, PhD - Johns Hopkins University
8:30 am - 9:00 am PresentationRepetitive DNA Vaccination Elicits PAP Antigen-Specific T Cell Immune Responses in Patients with Castrate-Resistant Prostate Cancer
Douglas G. McNeel, MD, PhD - University of Wisconsin
9:00 am - 9:15 am Intradermal Immunization with a Novel mRNA Based Vaccination Technology Induces Strong T and B Cell Responses in Phase I/ IIa Trials in Non-Small Cell Lung Cancer (NSCLC) and Prostate Carcinoma (PCA)
Birgit Scheel, PhD - CureVac GmbH
9:15 am - 9:30 am PresentationLymphoid and Myeloid Biomarkers for Clinical Outcome of Ipilimumab and Prostate GVAX Treatment: Tumor-related CTLA-4 Expression by CD4+ T Cells as a Dominant Predictor of Survival
Tanja D. De Gruijl, PhD - VU University Medical Center
9:30 am - 9:45 am Comprehensive Characterization of Polyomavirus BK Large Tumor Antigen Epitopes to Promote the Expansion of Effector T Lymphocytes in Prostate Cancer Patients
Maurizio Provenzano, MD, PhD - University Hospital of Zurich
9:45 am - 10:15 am PresentationCombining Vaccines with Other Therapeutics: A Strategy to Accelerate Proof of Concept Studies
James L. Gulley, MD, PhD, FACP - National Cancer Institute
10:15 am Annual Meeting Adjourns
10:15 am - 12:00 pm Hot Topic Symposium: Targeting the Next Generation of Inhibitory Pathways
   

 

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.